title: Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).
abstract: We conducted a phase 1/2 trial combining lenalidomide (R) with adriamycin (A) and dexamethasone (D) for relapsed and relapsed-refractory myeloma to determine tolerability and efficacy of this novel regimen, RAD, delivered for six 28-day cycles. A total of 69 intensively pretreated patients with a median age of 65 years (range, 46-77 years) were enrolled. Using pegfilgrastim (G), the maximum tolerated dose (MTD) was formally not reached at the highest dose level (R, 25 mg on days 1-21; A, 9 mg/m(2) intravenously on days 1-4; and D, 40 mg on days 1-4 and 17-20; dose level 5+G), which was then used to determine efficacy. Grades 3/4 neutropenia and thrombocytopenia were seen in 48% and 38% of patients, respectively. Thromboembolic events occurred in 4.5% and severe infections in 10.5% of patients. On an intent-to treat analysis, overall response rate (ORR) was 73% for the whole study and 77% including 74% complete response (CR) plus very good partial response (VGPR) for dose level 5+G. Response rates and progression-free survival did not differ between relapsed and relapsed-refractory patients. Deletion of chromosome 17p and elevated beta(2)-microglobulin were associated with significantly inferior response and shortened time to progression. In conclusion, RAD induces substantial and durable remission with an acceptable toxicity profile in patients with relapsed and relapsed-refractory myeloma. This trial was registered at www.ClinicalTrials.gov as no. NCT00306813.
authors.affiliation: Department of Internal Medicine II, Division of Hematology and Medical Oncology, University Hospital Wuerzburg and Early Clinical Development Unit of Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany. knop_s@klinik.uni-wuerzburg.de
authors.forename: Stefan
authors.initials: S
authors.lastname: Knop
authors.forename: Christian
authors.initials: C
authors.lastname: Gerecke
authors.forename: Peter
authors.initials: P
authors.lastname: Liebisch
authors.forename: Max S
authors.initials: MS
authors.lastname: Topp
authors.forename: Uwe
authors.initials: U
authors.lastname: Platzbecker
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezer
authors.forename: Christina
authors.initials: C
authors.lastname: Vollmuth
authors.forename: Karina
authors.initials: K
authors.lastname: Falk
authors.forename: Axel
authors.initials: A
authors.lastname: Glasmacher
authors.forename: Uwe
authors.initials: U
authors.lastname: Maeder
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
authors.forename: Ralf C
authors.initials: RC
authors.lastname: Bargou
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D018450:Disease Progression; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D016879:Salvage Therapy; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D004317:Doxorubicin; D000077269:Lenalidomide